FGFC1は,アポトーシスとピロプトーシスを誘発することによって,急性骨髄性白血病におけるAra-C抵抗を克服する
Xiaohui Hu1, Zhijian Li1, Rui Zhou1
1International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Frontiers in pharmacology
|September 2, 2025
まとめ
FGFC1は,急性骨髄性白血病 (AML) の化学療法抵抗を,アポトーシスとピロトーシスを誘導することによって克服する. この天然化合物はミトコンドリアの機能障害と ROSの蓄積を標的とし,薬剤耐性AMLに対する新しい戦略を提供します.
科学分野:
- 腫瘍学
- 分子生物学
- 薬理学について
背景:
- 急性骨髄性白血病 (AML) の死亡率は高く,しばしば化学療法に対する耐性がある.
- サイトラビン (Ara- C) は主要なAML治療法ですが,耐性が有効性を制限しています.
- 新しい治療戦略は,AMLにおけるAra-C耐性を克服するために不可欠です.
研究 の 目的:
- FGFC1がAMLにおけるAra-C耐性を克服する可能性を調査する.
- FGFC1がAML細胞に影響するメカニズムを探る
- 薬剤耐性AMLの治療候補としてFGFC1を評価する.
主な方法:
- Ara- C耐性AML細胞をFGFC1で治療する
- アポプトーシスとパイロプトーシス誘導の分析
- ミトコンドリア機能障害と活性酸素種 (ROS) レベルの調査
- カスパース3の活性化とシトクロームcの放出の評価
- PI3K/Akt/mTOR信号経路の評価について
主要な成果:
- FGFC1はAML細胞におけるAra- C抵抗を効果的に克服しました.
- FGFC1はアポプトーシスとピロプトーシスの両方を誘発した.
- そのメカニズムはミトコンドリア機能障害とROSの増加であり,Caspase-3の活性化につながった.
- FGFC1はPI3K/Akt/mTORシグナル伝達経路を阻害し,細胞の成長を抑制しました.
結論:
- FGFC1はAMLにおけるAra-C耐性を克服する可能性を示しています.
- FGFC1誘発のアポプトーシスとピロプトーシスは新しい治療法です.
- FGFC1は薬剤耐性AMLの治療法としてさらなる調査を必要としています.
関連する概念動画
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:17The Extrinsic Apoptotic Pathway
6.6K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.6K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:30Apoptosis
11.9K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.9K
01:31The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K